Zydus Lifesciences has successfully completed its $166.4 million acquisition of Assertio Holdings, marking a significant milestone in the pharmaceutical company's expansion strategy. According to latest reports from PTI and The Economic Times, the merger has been completed with Assertio becoming a wholly owned subsidiary of Zydus Lifesciences through a cash tender offer. This acquisition represents a strategic move by Zydus Lifesciences to strengthen its pharmaceutical portfolio through the integration of Assertio Holdings operations, which specializes in specialty and oncology supportive care therapies. The successful completion of the tender offer demonstrates strong shareholder support, with 4,286,488 shares validly tendered representing 66.32% of issued and outstanding shares.
The tender offer received strong acceptance from Assertio shareholders, with 4,286,488 shares validly tendered and not withdrawn, representing 66.32% of issued and outstanding shares as of the expiration time. As reported in the SEC filing, the purchaser accepted these shares and will pay $23.50 per share in cash promptly in accordance with the Offer and Merger Agreement. The merger under Section 251(h) of the DGCL is expected to close on June 16, 2026, after which Assertio will be a wholly owned subsidiary and its common stock will be delisted from Nasdaq. Untendered shares will be cashed out at the same offer price.
Following the completion of the merger, Assertio's common stock will no longer be listed or traded on the Nasdaq Global Market. As reported by PTI and The Economic Times, this development means that Assertio Holdings will operate as a private entity within the Zydus Lifesciences group structure. The removal of Nasdaq listing eliminates the public trading component of Assertio's operations and consolidates the company's ownership under Zydus Lifesciences. Subsequent steps include delisting the shares and terminating registration under the Exchange Act as promptly as practicable.
The acquisition was executed through Zydus Worldwide DMCC, a subsidiary of Zydus Lifesciences, using its wholly-owned acquisition arm Zara Merger Sub Inc. According to the regulatory filing, the company paid $23.50 per share in cash for all outstanding shares of Assertio Holdings Inc. The total consideration of $166.4 million (over ₹1,590 crore) represents a significant investment in expanding Zydus Lifesciences' pharmaceutical capabilities in the US market. The transaction was structured under Section 251(h) of the DGCL, which allows for merger completion without stockholder vote once sufficient shares are tendered.
The acquisition of Assertio Holdings represents a strategic move by Zydus Lifesciences to expand its pharmaceutical operations through the integration of Assertio's specialized business capabilities in specialty and oncology supportive care therapies. According to The Economic Times, this merger aligns with Zydus Lifesciences' growth strategy and provides the company with enhanced capabilities in the pharmaceutical sector, particularly in the US market where Assertio has established its presence in oncology supportive care therapies. The successful completion of the tender offer with 66.32% acceptance rate demonstrates strong shareholder support for the transaction. Following the acquisition announcement, Zydus Lifesciences shares remain in focus as the company continues to strengthen its pipeline of innovative drugs, with the stock maintaining a market capitalisation of nearly ₹1.09 lakh crore and a P/E ratio of around 22x.
